Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of… bypharmanewsdailyJanuary 20, 2019